R. Baillie et al., Prognostic value of vascularity and vascular endothelial growth factor expression in non-small cell lung cancer, J CLIN PATH, 54(2), 2001, pp. 116-120
Citations number
34
Categorie Soggetti
Research/Laboratory Medicine & Medical Tecnology","Medical Research Diagnosis & Treatment
Aims-High expression of the angiogenic factor vascular endothelial growth f
actor (VEGF) in tumours has been found to be associated with poor prognosis
in some studies, but not in others. The aims of this study were to determi
ne the prognostic value of VEGF in operable non-small cell lung cancer (NSC
LC) and its possible association with vascularity.
Methods-Sections from 81 NSCLC archival specimens were stained with antibod
ies to von Willebrand factor (VWF) and VEGF. Vascularity was measured by th
e average density of VWF positive vessels. VEGF expression in tumour cells
was assessed by consensus of two independent observers according to three i
ndices, namely: (I) percentage of area stained, (2) intensity of staining,
and (3) final score (product of area and intensity).
Results-VEGF immunoreactivity was present in all tumours and adjacent norma
l lung tissue. None of the three VEGF indices was associated with vasculari
ty or the clinical parameters examined. Mean survival times were shorter in
patients with high VEGF expression, but the difference was not significant
. This applied to the full cohort of patients, or when analysed separately
according to present normal However, high VEGF expression was associated wi
th poor survival in patients with high vascularity (p = 0.02). VEGF had no
discriminant value among patients with low vascularity. Vascularity had no
prognostic value, except for late stage patients (UICC stages II and IIIa c
ombined; n = 36), where high vascularity was associated with longer surviva
l (p = 0.01).
Conclusions-VEGF on its own has no prognostic value in NSCLC, but may becom
e a useful indicator when combined with vascularity. VEGF may play a physio
logical role in the normal lung.